Enfortumab vedotin

EV-301

Enfortumab vedotin EV-301

PRELIMINARY SCORE

CURATIVE

NON-CURATIVE

OS

ADJUSTMENTS

Quality of life

?

QoL data pending

Serious and disabling adverse effects

Other adjustments

Enfortumab vedotin EV-301

FINAL SCORE

CURATIVE

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

4

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers
Therapeutic Indication: Treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor
Experimental Arm: Enfortumab vedotin
Control Arm: Investigator-chosen ChT (standard docetaxel, paclitaxel or vinflunine)